Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-06.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101 Metabolic Reprogramming in Thyroid Cancer
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism



Page Path
HOME > Endocrinol Metab > Ahead-of print > Article
Review Article Metabolic Reprogramming in Thyroid Cancer
Sang-Hyeon Ju1orcid , Minchul Song1, Joung Youl Lim1, Yea Eun Kang1,2, Hyon-Seung Yi1,2, Minho Shong3orcid

DOI: https://doi.org/10.3803/EnM.2023.1802 [Epub ahead of print]
Published online: June 10, 2024
  • 13 Download
  • 0 Crossref
  • 0 Scopus
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea
2Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea
3Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
Corresponding author:  Minho Shong, Tel: +82-42-350-0236, Fax: +82-42-280-6990, 
Email: minhos@kaist.ac.kr
Received: 15 August 2023   • Revised: 25 January 2024   • Accepted: 12 March 2024

Thyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality. Inhibiting RET and BRAF kinases has emerged as a potential therapeutic strategy for the treatment of thyroid cancer, particularly in cases of advanced or aggressive disease. However, the development of resistance mechanisms may limit the efficacy of these kinase inhibitors. Therefore, developing precise strategies to target thyroid cancer cell metabolism and overcome resistance is a critical area of research for advancing thyroid cancer treatment. In the field of cancer therapeutics, researchers have explored combinatorial strategies involving dual metabolic inhibition and metabolic inhibitors in combination with targeted therapy, chemotherapy, and immunotherapy to overcome the challenge of metabolic plasticity. This review highlights the need for new therapeutic approaches for thyroid cancer and discusses promising metabolic inhibitors targeting thyroid cancer. It also discusses the challenges posed by metabolic plasticity in the development of effective strategies for targeting cancer cell metabolism and explores the potential advantages of combined metabolic targeting.

Related articles

Endocrinol Metab : Endocrinology and Metabolism